Nancy JoAnn Johnson bought $414k of BLLN
See Remarks at BillionToOne, Inc.. 6,900 shares at an average of $60.00, traded Nov 7, 2025, filed Nov 12, 2025.
Score components
- +15RoleOfficer
- +16Trade size$414k at market
- +6Relative to holdingsHoldings up 24%
- +10Price context0% above the 52-week low
- +15Cluster6 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-25-278118, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 7, 2025 | JOther Common Stock | -29,000 | - | - | 0 | Nov 12, 2025 |
| Nov 7, 2025 | JOther Class A Common Stock | +29,000 | - | - | 29,000 | Nov 12, 2025 |
| Nov 7, 2025 | POpen-market purchase Class A Common Stock | +6,900 | $60.00 | $414k | 35,900 | Nov 12, 2025 |
| Nov 7, 2025 | JOther Stock Option (right to buy)derivative | -125,000 | - | - | 0 | Nov 12, 2025 |
| Nov 7, 2025 | JOther Stock Option (right to buy)derivative | +125,000 | - | - | 125,000 | Nov 12, 2025 |
| Nov 7, 2025 | JOther Stock Option (right to buy)derivative | -25,000 | - | - | 0 | Nov 12, 2025 |
| Nov 7, 2025 | JOther Stock Option (right to buy)derivative | +25,000 | - | - | 25,000 | Nov 12, 2025 |
| Nov 7, 2025 | JOther Stock Option (right to buy)derivative | -25,000 | - | - | 0 | Nov 12, 2025 |
| Nov 7, 2025 | JOther Stock Option (right to buy)derivative | +25,000 | - | - | 25,000 | Nov 12, 2025 |
| Nov 7, 2025 | JOther Stock Option (right to buy)derivative | -40,000 | - | - | 0 | Nov 12, 2025 |
| Nov 7, 2025 | JOther Stock Option (right to buy)derivative | +40,000 | - | - | 40,000 | Nov 12, 2025 |
| Nov 7, 2025 | JOther Stock Option (right to buy)derivative | -20,000 | - | - | 0 | Nov 12, 2025 |
| Nov 7, 2025 | JOther Stock Option (right to buy)derivative | +20,000 | - | - | 20,000 | Nov 12, 2025 |
| Nov 7, 2025 | JOther Stock Option (right to buy)derivative | -40,000 | - | - | 0 | Nov 12, 2025 |
| Nov 7, 2025 | JOther Stock Option (right to buy)derivative | +40,000 | - | - | 40,000 | Nov 12, 2025 |
Related signals
Other insiders at BillionToOne, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 29Weak | BillionToOne, Inc. | John Roderick ten Bosch SVP of Laboratory Operations | $298k 2,834 shares | -13% | |
| 40Moderate | BillionToOne, Inc. | David Tsao Chief Technology Officer | $2.2M 20,000 shares | -95% | |
| 50Moderate | BillionToOne, Inc. | Oguzhan Atay Chairman and CEO | $1.3M 10,999 shares | -132% | |
| 21Weak | BillionToOne, Inc. | John Roderick ten Bosch SVP of Laboratory Operations | $170k 1,416 shares | -6% | |
| 31Weak | BillionToOne, Inc. | David Tsao Chief Technology Officer | $417k 3,333 shares | -77% | |
| 21Weak | BillionToOne, Inc. | John Roderick ten Bosch SVP of Laboratory Operations | $151k 1,416 shares | -6% | |
| 40Moderate | BillionToOne, Inc. | Thomas P. Lynch See Remarks | $3.9M 35,112 shares | -98% | |
| 50Moderate | BillionToOne, Inc. | Oguzhan Atay Chairman and CEO | $3.0M 30,331 shares | -121% | |
| 21Weak | BillionToOne, Inc. | John Roderick ten Bosch SVP of Laboratory Operations | $138k 1,416 shares | -5% | |
| 40Moderate | BillionToOne, Inc. | David Tsao Chief Technology Officer | $2.0M 20,000 shares | -95% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.